Phase I human safety testing of 18-methoxycoronaridine (18-MC) as a treatment for leishmaniasis.

Trial Profile

Phase I human safety testing of 18-methoxycoronaridine (18-MC) as a treatment for leishmaniasis.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2014

At a glance

  • Drugs 18-methoxycoronaridine (Primary)
  • Indications Leishmaniasis
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Sep 2014 New trial record
    • 23 Sep 2014 Interim results published in a Savant HWP media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top